Lobbying client
RIGEL PHARMACEUTICALS INC.
Biotechnology company focused on novel small molecule drugs for rare diseases
Filings
12
Filed by
1
Reported in-house
—
Reported by firms
$30,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2020 to 2023
Filings
12 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
2nd Quarter - Termination (No Activity) 2nd Quarter 2023
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2023
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
4th Quarter - Report (No Activity) 4th Quarter 2022
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2022
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
2nd Quarter - Report (No Activity) 2nd Quarter 2022
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2022
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
4th Quarter - Report (No Activity) 4th Quarter 2021
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
3rd Quarter - Report 3rd Quarter 2021
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
1st Quarter - Report 1st Quarter 2021
|
ARNOLD & PORTER KAYE SCHOLER LLP | — reported |
|
2nd Quarter - Report 2nd Quarter 2021
|
ARNOLD & PORTER KAYE SCHOLER LLP | $20,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| ARNOLD & PORTER KAYE SCHOLER LLP | 11 | $30,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 5 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.